Objective To investigate the effect of linezolid on platelets in patients with acute myeloid leukemia(AML)and analyze the safety profile of linezolid by comparing the platelet count and bleeding risk of linezolid during bone marrow suppression in patients after chemotherapy for AML.Methods A retrospective study was conducted on patients who underwent chemotherapy for AML in a tertiary hospital from January 2020 to November 2024.The patients treated with linezolid and those not receiving linezolid were matched in a 1∶2 ratio.The safety of linezolid during bone marrow suppression after chemotherapy for AML was analyzed in terms of platelet count＜20×109/L,＜50×109/L,minimum platelet count,total platelet transfusion volume,and clinical bleeding events.Results A total of 126 patients were enrolled,including 42 patients receiving linezolid and 84 patients not receiving linezolid.There was no significant difference between linezolid group and control group in the days for platelet count＜20×109/Land＜50×109/L.No life-threatening severe bleeding events were reported in either group.The time to platelet recovery and time to platelet count increase prolonged significantly in patients who received linezolid treatment for more than 7 days during bone marrow suppression.Albumin＜35 g/L may prolong the time to platelet count increase.Conclusions This study suggests that short-term use of linezolid for not more than 7 days is safe during bone marrow suppression in patients after chemotherapy for AML.When linezolid is used for more than 7 days,the time required for platelet recovery and platelet count increase will be significantly prolonged.In cases of albumin＜35 g/L,the time required for platelet count increase may be prolonged.These findings can inform clinical decision-making and help optimize infection management strategies for AML patients.

ObjectiveThis study aimed to explore the correlation between the quality of life （QOL） and different traditional Chinese medicine （TCM） syndromes in patients with myasthenia gravis （MG）， identifying potential influencing factors to provide new insights for clinical interventions and improving the QOL of patients with MG. MethodsA questionnaire survey was conducted on 93 adults with MG who visited the Department of Neurology at the Affiliated Hospital of Changchun University of Chinese Medicine from March 2023 to January 2024. Statistical analysis was performed on the clinical data collected using SPSS 24.0 software. ResultsAmong the 93 patients with MG， the average score for myasthenia gravis quality of life-15 （MGQOL-15） was 17.65±6.27， and that for the 36-item short form health survey （SF-36） was （106.13±11.83） scores. The QOL was rated as good for 16 patients and moderate for 77 patients. There were no statistically significant differences in the scores of MGQOL-15， SF-36， and their individual scales by gender or education level. Age showed statistically significant differences in MGQOL-15 and the role physical （RP） scale （P<0.05）， and occupational type showed significant differences in the vitality （VT） scale （P<0.01）. The Myasthenia Gravis Foundation of America （MGFA） classification had statistical significance on the total SF-36 score （P<0.01）， VT scale （P<0.01）， role emotional （RE） scale （P<0.05）， social functioning （SF） scale （P<0.05）， and physical functioning （PF） scale （P<0.01）. Among patients with different TCM syndromes， there were significant differences in MGQOL-15 scores （F=4.919， P<0.01）. Moreover， significant differences were observed in SF-36 scores （P<0.01）， VT scale （P<0.01）， RE scale （P<0.05）， mental health （MH） scale （P<0.01）， and SF scale （P<0.05）. ConclusionFactors affecting the QOL of patients with MG include age， occupational type， and clinical classification of MG. Specifically， a greater impact on the QOL of older patients is observed， while physical laborers have a poorer QOL compared to non-physical laborers. Patients classified as MGFA type Ⅱ and higher have a poorer QOL. Additionally， there is a potential correlation between the QOL and TCM syndromes， with patients presenting with spleen and kidney Qi deficiency having a lower QOL than those with spleen and stomach Qi deficiency or Qi and Yin deficiency， which is particularly evident in the VT， RE， MH， and SF scales.

Objective To investigate the effect of linezolid on platelets in patients with acute myeloid leukemia(AML)and analyze the safety profile of linezolid by comparing the platelet count and bleeding risk of linezolid during bone marrow suppression in patients after chemotherapy for AML.Methods A retrospective study was conducted on patients who underwent chemotherapy for AML in a tertiary hospital from January 2020 to November 2024.The patients treated with linezolid and those not receiving linezolid were matched in a 1∶2 ratio.The safety of linezolid during bone marrow suppression after chemotherapy for AML was analyzed in terms of platelet count＜20×109/L,＜50×109/L,minimum platelet count,total platelet transfusion volume,and clinical bleeding events.Results A total of 126 patients were enrolled,including 42 patients receiving linezolid and 84 patients not receiving linezolid.There was no significant difference between linezolid group and control group in the days for platelet count＜20×109/Land＜50×109/L.No life-threatening severe bleeding events were reported in either group.The time to platelet recovery and time to platelet count increase prolonged significantly in patients who received linezolid treatment for more than 7 days during bone marrow suppression.Albumin＜35 g/L may prolong the time to platelet count increase.Conclusions This study suggests that short-term use of linezolid for not more than 7 days is safe during bone marrow suppression in patients after chemotherapy for AML.When linezolid is used for more than 7 days,the time required for platelet recovery and platelet count increase will be significantly prolonged.In cases of albumin＜35 g/L,the time required for platelet count increase may be prolonged.These findings can inform clinical decision-making and help optimize infection management strategies for AML patients.

Abdominal aortic aneurysm (AAA) is a life-threatening large-vessel disease closely associated with immune and inflammation-related mechanisms. During the development of AAA,innate immune cells play a pivotal role in the immune-mediated inflammatory infiltration and destruction of the aortic wall. These cells include neutrophils,monocytes,macrophages,dendritic cells,mast cells,natural killer cells,innate lymphoid cells,and invariant natural killer T cells. Although various immune cells have been progressively identified in the study of AAA,their activation mechanisms and functions remain to be further elucidated. This article summarizes the roles of innate immune cells in the progression of AAA and discusses the regulatory mechanisms of their activation in this disease,providing a theoretical basis for research on AAA progression.

Abdominal aortic aneurysm (AAA) is a life-threatening large-vessel disease closely associated with immune and inflammation-related mechanisms. During the development of AAA,innate immune cells play a pivotal role in the immune-mediated inflammatory infiltration and destruction of the aortic wall. These cells include neutrophils,monocytes,macrophages,dendritic cells,mast cells,natural killer cells,innate lymphoid cells,and invariant natural killer T cells. Although various immune cells have been progressively identified in the study of AAA,their activation mechanisms and functions remain to be further elucidated. This article summarizes the roles of innate immune cells in the progression of AAA and discusses the regulatory mechanisms of their activation in this disease,providing a theoretical basis for research on AAA progression.

AIM: To explore the roles of heat shock protein 90 (HSP90) in the blockage of hydrogen sulfide (H2S) against chemical hypoxia-mimetic agent (cobalt chloride, CoCl_2)-induced oxidative stress injuries in H9c2 cardiac cell. METHODS: H9c2 cells were treated with CoCl_2 to set up the chemical hypoxia-induced the model of cardiomyocyte injury. Sodium hydrosulfide (NaHS, a H2S donor) was added into medium for 30 min before CoCl_2 treatment. ATP content was detected by high performance liquid chromatogram (HPLC). Mitochondrial membrane potential (MMP) was measured by rhodamine123 (Rh123) staining and photofluorography. The activity of superoxide dismutase (SOD) was observed using a SOD kit. The expression of heme oxygenase-1 (HO-1) was evaluated by Western blotting. RESULTS: CoCl_2 at concentration of 600 μmol/L significantly reduced SOD activity, ATP level and MMP, and enhanced the expression of HO-1 in H9c2 cells. Pretreatment with 400 μmol/L NaHS dramatically inhibited the cytotoxicity induced by CoCl_2, increased SOD activity, ATP level and MMP, decreased HO-1 expression. 17-allylamino-17 demethoxygeldanamycine(17AAG), an inhibitor of HSP90, obviously blocked the inhibitory effect of H2S on the CoCl_2-induced cytotoxicity, reduced the levels of ATP and MMP, increased HO-1 expression. However, no significantly influence on SOD activity was observed. CONCLUSION: HSP90 may mediate the cardioprotection of H2S via inhibiting the oxidative stress induced by chemical hypoxia.

Five patients with Peutz-Jeghers Syndrome(PJS) have been reported in this paper. One ofthem developed polypous malignancy in the rec-tum, one associated with bladder canaer. The au-thers have once performed multiple operations, in-cluded small bower Roux-Y anastomosis keepedpylorus for a patiet with duodenal obstruction in-duced by polyps. The questions related with surgi-cal management is PJS are discussed principally inthis paper.